The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 39 | — | 20.1x | Near average | |
Growth | 51 | -100.0% | 5.6% | Near average | |
Quality | 5 | -305.5% | 7.6% | Below average | |
Safety | 46 | 0.6x | 0.4x | Near average | |
Capital Return | 95 | — | 2.19% | Above average | |
Momentum | 33 | — | — | Below average | |
Sentiment | 23 | — | — | Below average |
INmune Bio, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy INmune Bio, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Analyst coverage for INMB has seen a notable contraction in the number of active opinions, as the number of analysts contributing to the price target dropped from 3 to only 1 analyst in recent days, despite the price target stabilizing at 22. This shrinkage in the analytical database indicates a state of uncertainty or anticipation of new clinical catalysts, especially with the large gap between the current price (1.41) and the ambitious target.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.